Efficacy, safety, and adherence to intravenous bisphosphonate treatment in postmenopausal osteoporosis

I.B. Belyaeva

I.I. Mechnikov North-Western State Medical University, Saint Petersburg

Postmenopausal osteoporosis is one of the most common clinical types of osteoporosis. The article presents the main stages of the osteoporosis pathogenesis, directly related to the formation of estrogen deficiency and bone remodeling disorder. Particular attention is paid to the efficacy and safety of bisphosphonates (BP) administration, which are the first-line drugs in the treatment of this pathology. The article also presents the ability of BP to inhibit pathological bone resorption and stimulate bone formation and highlights the data of international placebo-controlled and Russian follow-up studies, which indicate the high efficacy of ibandronic acid (IA). It was noted that the use of IA with intravenous administration of 3 mg once every 3 months leads to the restoration of bone metabolism, an increase in bone mineral density (BMD) and strength, and reduces the risk of vertebral and extravertebral fractures in high-risk patients. Analysis of the results concerning the dynamic follow-up of patients receiving IA indicates its aftereffect during the 12 months after the end of treatment for the preservation of the spine BMD. The benefit of ibandronate intravenous administration route is the possibility for patients with gastrointestinal pathology (esophageal ulcers, esophagitis), as well as a reduction in the frequency of use (once every 3 months), which increases adherence to therapy.

Keywords: postmenopausal osteoporosis, bisphosphonates, ibandronic acid, compliance, cardiovascul ar risk.

For citation: Belyaeva I.B. Efficacy, safety, and adherence to intravenous bisphosphonate treatment in postmenopausal osteoporosis. RMJ. 2021;4:74–77.